Ipilimumab plus decitabine for patients with MDS or AML in posttransplant or transplant-naïve settingsJacqueline S. Garcia, Robert J. Soiffer, Paul Koller et al.|Blood|2022Cited by 51
Mechanisms of response and resistance to combined decitabine and ipilimumab for advanced myeloid diseaseLivius Penter, Catherine J. Wu, Yang Liu et al.|Blood|2023Cited by 51
Mechanisms of Response and Resistance to Combination Decitabine and Ipilimumab for Transplant Naïve and Post-Transplant AML/MDSLivius Penter, Catherine J. Wu, Yang Liu et al.|Blood|2022Cited by 2